Primary Assessment Method: Median Progression-Free Survival, Arm B
Number of patients evaluable for toxicity	87 (43 in Arm A, 44 in Arm B)
Evaluation method	RECIST 1.1
Response assessment, CR	1 (2.3%)
Response assessment, PR	5 (11.4%)
Response assessment, SD	15 (34.1%)
Response assessment, PD	18 (40.9)
Median duration assessments, PFS	2.3 months (95% CI, 2.0-3.5)
Median duration assessments, OS	7.2 months (95% CI, 4.9-8.1)
Median duration of treatment	2.0 cycles